Last year, the US Food and
Drug Administration approved a targeted drug called osimertinib, which inhibits the standard EGFRmutations as well as T790M, but people who respond to it tend to relapse within a y
Drug Administration approved a targeted
drug called osimertinib, which inhibits the standard EGFRmutations as well as T790M, but people who respond to it tend to relapse within a y
drug called
osimertinib, which inhibits the standard EGFRmutations as well as T790M, but people who respond to it tend to relapse within a year.
One of these promising new compounds is
osimertinib, a third - generation EGFR - mutant inhibitor that has been approved by the US Food and
Drug Administration (FDA) for EGFR T790M — positive NSCLC.